SPYRAL GEMINI Pilot Study
Medtronic Vascular · NCT06907147
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–80 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 175
- US sites recruiting
- 12
- Study start
- May 1, 2025
- Record last updated
- October 20, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.
Being studied: Multi-Organ Denervation Gemini System
Conditions: Hypertension; Vascular Diseases; Cardiovascular Diseases; Chronic Kidney Diseases; Diabetes Mellitus
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
All Subjects (both cohorts):
- ≥18 and ≤80 years of age.
- Diagnosed with HTN and has a baseline office SBP ≥150 mmHg and \<180 mmHg and an office DBP ≥ 90 mmHg.
- 24-hour average SBP ≥140 mmHg and \<170 mmHg measured by ABPM at Baseline.
Exclusion Criteria
- Individual lacks appropriate renal artery OR common hepatic artery anatomy.
- Prior renal or hepatic denervation.
- History of NYHA Class III or IV heart failure within 6 months of screening visit.
- Stroke or transient ischemic attack (TIA) within 6 months of screening visit or any history of stroke leading to permanent disability.
- Documented Type 1 diabetes or use of insulin within 6 months.
- Secondary cause of hypertension.
- Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement.
- Estimated glomerular filtration rate (eGFR) of \<40
- Pregnant, nursing or planning to become pregnant during the study.
- Primary pulmonary arterial hypertension.
- History or evidence of active / suspected chronic liver or biliary disease.
- Current or chronic pancreatitis.
Recruiting US locations
Stanford Hospital and Clinics
Stanford, CA 94305
Site contact: Maria Perlas · 650-723-2094 · mperlas@stanford.edu
Orlando Health Heart & Vascular Institute
Orlando, FL 32806
Site contact: Farhan J. Khawaja, MD · 321-841-6444 · farhan.khawaja@orlandohealth.com
BayCare Health System Mease Countryside Hospital
Safety Harbor, FL 34695
Site contact: Kristy Roakes · 727-724-8611 · kristy.roakes@baycare.org
Piedmont Heart Institute
Atlanta, GA 30309-1281
Site contact: David Kandzari, MD · 404-605-2800 · david.kandzari@piedmont.org
Beth Israel Deaconess Medical Center
Boston, MA 02215
Site contact: Jenifer Kaufman, DNP · 617-632-8956 · jmkaufma@bidmc.harvard.edu
Henry Ford Providence Hospital
Southfield, MI 48075-4818
Site contact: Yulia Abidov · 248-849-5328 · yabidov1@hfhs.org
North Mississippi Medical Center
Tupelo, MS 38801-4934
Site contact: Brittany Cook · 662-620-6853 · brittany.cook@nmhs.net
Renown Regional Medical Center
Reno, NV 89502
Site contact: Kristen Gurnea, MPH · kristen.gurnea@renown.org
Virtua Our Lady of Lourdes Hospital
Camden, NJ 08103
Site contact: Kristin Broderick, BS · 609-969-1175 · kbroderick@virtua.org
University of North Carolina (UNC) Memorial Hospital
Chapel Hill, NC 27599
Site contact: George Stouffer, MD · 984-974-7244 · rick_stouffer@med.unc.edu
Baylor Heart & Vascular Hospital
Dallas, TX 75226
Site contact: Merielle H. Boatman, MBA · 214-820-2273 · merielle.boatman@bswhealth.org
UT Health East Texas
Tyler, TX 75701
Site contact: Elizabeth Seal, BSc, CCRC · 903-510-7291 · elizabeth.seal@uthet.com
Study contacts (from the official record)
- Cecile Mahoney · +17635051057 · Cecile.C.Mahoney@medtronic.com
Similar studies in California
All diabetes studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
TIXiMED, Inc.
- Location
- Chula Vista, CA
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Regeneron Pharmaceuticals
- Location
- Glendale, CA
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of…
AstraZeneca
- Location
- Glendale, CA + 3 other US sites
- Eligibility basics
- Ages 18–75